Abstracts

Developing an Ontology-Based Platform to Detect Serine Protease Involvement in BALT Lymphoma Patients with COVID-19 & Connect Them to Clinical Trials

Introduction:

Kirk McGregor ;

Yan Leyfman ;

Samarth Sandeep ;

Chandler H. Park ;

11/04/2022

Exploring Barriers to Bone-Targeted Agent Initiation in Multiple Myeloma

Introduction:

Colm Somers ;

Maya Charan ;

David H. Henry ;

11/04/2022

De Novo Acute Myeloid Leukemia in a Patient with Chronic Myeloid Leukemia Under Excellent Control with Tyrosine Kinase Inhibitor

Introduction:The advent of tyrosine kinase inhibitors (TKI) has significantly improved the survival of patients with chronic myeloid leukemia (CML). A second de novo myeloid malignancy su...

Kok-Hoy Chan ;

Adan Rios ;

11/04/2022

Upper Gastrointestinal (GI) Morbidity, Peptic Ulcer Risk, and Proton Pump Inhibitor (PPI)/H2 Blocker (H2B) Use in Patients Treated with Bruton‚Äôs Tyrosine Kinase Inhibitors (BTKis) During Routine Care

Introduction:Novel oncolytic agents, including the first-in-class BTKi ibrutinib, have transformed CLL/SLL and MCL treatment. Later-approved BTKis have offered additional treatment choice...

Sofia Xavier ;

Maria João Moreira ;

José Cotter ;

Francisca Dias de Castro ;

Rui Magalhaes ;

11/04/2022

Poor response Hemophagocytic Lymphohistiocytosis Secondary to EBV Reactivation in a Patient with COVID-19 Infection

Introduction:Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. Acquired HLH can be triggered by viral infections, with Epstein-Barr virus (EBV) am...

Sumiti Kumar ;

Julia Budde ;

Anil Baral ;

Racine Reinoso ;

Delatre Lolo , MD;

Alexandra Dolgetta ;

Kimbo Sandal ;

Andrea Popescu ;

Daniel Sacoto ;

Bryan Quintanilla ;

Emily Sayegh ;

Maria Palad ;

11/04/2022

Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial

Introduction:More tolerable, readily available treatment options are needed for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) to induce deep, durable responses. ...

Michael Roost Clausen ;

Mariana Sacchi ;

Catherine Thieblemont ;

Martin Hutchings ;

Tycel Phillips ;

Pieternella Lugtenburg ;

Herve Ghesquieres ;

Chan Y. Cheah ;

Young R. Do ;

Tatyana Feldman ;

Robin Gasiorowski ;

Wojciech Jurczak ;

Tae Min Kim ;

David J. Lewis ;

Mariolein van der Poe ;

Michelle L. Poon ;

Thomas Doerr ;

Nurgul Kilavuz ;

David Cunningham ;

Menghui Chen ;

11/04/2022

Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis

Introduction:

Thomas G. Martin III, MD;

Michele Cavo ;

Wolfgang Knauf ;

Nobuhiro Tsukuda ;

Elisabet E. Manasanch ;

Zhenming Zhao ;

Christina Tekle ;

Meral Beksac ;

11/04/2022

Polatuzumab Vedotin Combined with Immunochemotherapy in Relapsed/Refractory Patients with Diffuse Large B-cell Lymphoma: A Retrospective, Real Life Study of KROHEM(Croatian Cooperative Group for Hematologic Disease)

Introduction:Despite therapeutic advances, patients with relapsed or refractory (R/R) DLBCL have a dire prognosis. Polatuzumab-vedotin (PoV), an antibody-drug conjugate (ADC) targeting an...

11/04/2022

Subcutaneous Epcoritamab Combined With Rituximab + Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update

Introduction:

Jacob H. Christensen ;

Sven de Vos , MD, PhD;

Harald Holte ;

Kim M. Linton ;

Aqeel Abbas ;

Minh Dinh ;

Brian Elliott ;

David Belada ;

Sirpa Leppä, ;